4,5,6 Since 2008, the Food and Drug Administration (FDA) and European Medicines Agency have required that new T2D pharmacotherapies undergo rigorous cardiovascular safety clinical trials using hard cardiovascular endpoints and more stringent statistical review
Unlike single or dual-action treatments, Retatrutide targets the GLP-1, GIP, and glucagon receptors all at once
The applications of GLP-1RAs extend far beyond diabetes management
All prices represent starting doses and are subject to change
A retrospective study found that the use of GLP1R agonists was associated with lower risk for 10 of the 13 obesity-associated cancers in type 2 diabetes patients although the mechanisms remain unclear, suggesting a need for further preclinical and clinical investigation 17
Here's the full breakdown